Altimmune shares cratered nearly 60% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Shares of Altimmune Inc. tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic fatty ...

Altimmune Inc (NASDAQ: ALT) shares plunged after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). The trial assessed three ...

Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeks GAITHERSBURG, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a ...

Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to ...

The latest international Altimmune Inc news and views from Reuters - one of the world's largest news agencies. ... Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle.

Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome ...